Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

Similar articles for PubMed (Select 20093041)

1.

Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products.

Goodrich RP, Doane S, Reddy HL.

Biologicals. 2010 Jan;38(1):20-30. doi: 10.1016/j.biologicals.2009.10.016. Epub 2010 Jan 25.

PMID:
20093041
2.

Pathogen-reduction systems for blood components: the current position and future trends.

Seghatchian J, de Sousa G.

Transfus Apher Sci. 2006 Dec;35(3):189-96. Epub 2006 Nov 15. Review.

PMID:
17110168
3.

Update on pathogen reduction technology for therapeutic plasma: an overview.

Solheim BG, Seghatchian J.

Transfus Apher Sci. 2006 Aug;35(1):83-90. Epub 2006 Aug 24. Review.

PMID:
16934528
4.

Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light.

Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP.

Transfusion. 2004 Jun;44(6):877-85.

PMID:
15157255
5.

Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma.

Smith J, Rock G.

Transfusion. 2010 Apr;50(4):926-31. doi: 10.1111/j.1537-2995.2009.02517.x. Epub 2009 Dec 29.

PMID:
20051060
6.

Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation.

Fast LD, DiLeone G, Marschner S.

Transfusion. 2011 Jul;51(7):1397-404. doi: 10.1111/j.1537-2995.2010.02984.x. Epub 2010 Dec 13.

PMID:
21155832
7.

Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation.

Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP.

Transfus Med Rev. 2008 Apr;22(2):133-53. doi: 10.1016/j.tmrv.2007.12.003. Review.

PMID:
18353253
8.

Pathogen reduction of blood components.

Solheim BG.

Transfus Apher Sci. 2008 Aug;39(1):75-82. doi: 10.1016/j.transci.2008.05.003. Epub 2008 Jul 3. Review.

PMID:
18602343
9.

Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 °C.

Ettinger A, Miklauz MM, Hendrix BK, Bihm DJ, Maldonado-Codina G, Goodrich RP.

Transfus Apher Sci. 2011 Feb;44(1):25-31. doi: 10.1016/j.transci.2010.12.005. Epub 2011 Jan 19.

PMID:
21251884
10.

Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.

Ambruso DR, Thurman G, Marschner S, Goodrich RP.

Transfusion. 2009 Dec;49(12):2631-6. doi: 10.1111/j.1537-2995.2009.02347.x. Epub 2009 Aug 18.

PMID:
19694996
11.

Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C.

Bihm DJ, Ettinger A, Buytaert-Hoefen KA, Hendrix BK, Maldonado-Codina G, Rock G, Giclas PC, Goodrich RP.

Vox Sang. 2010 Feb;98(2):108-15. doi: 10.1111/j.1423-0410.2009.01238.x. Epub 2009 Aug 30.

PMID:
19719460
12.

Pathogen reduction technology (Mirasol) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS.

Janetzko K, Hinz K, Marschner S, Goodrich R, Klüter H.

Vox Sang. 2009 Oct;97(3):234-9.

PMID:
19790298
13.

Pathogen inactivation techniques.

Pelletier JP, Transue S, Snyder EL.

Best Pract Res Clin Haematol. 2006;19(1):205-42. Review.

PMID:
16377551
14.
15.

Functional inactivation of white blood cells by Mirasol treatment.

Fast LD, Dileone G, Li J, Goodrich R.

Transfusion. 2006 Apr;46(4):642-8.

PMID:
16584442
16.

Evaluation of the Mirasol pathogen [corrected] reduction technology system against Babesia microti in apheresis platelets and plasma.

Tonnetti L, Proctor MC, Reddy HL, Goodrich RP, Leiby DA.

Transfusion. 2010 May;50(5):1019-27. doi: 10.1111/j.1537-2995.2009.02538.x. Epub 2009 Dec 18. Erratum in: Transfusion. 2010 Jul;50(7):1594.

PMID:
20030791
17.

Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion.

Feys HB, Van Aelst B, Devreese K, Devloo R, Coene J, Vandekerckhove P, Compernolle V.

Vox Sang. 2014 May;106(4):307-15. doi: 10.1111/vox.12106. Epub 2013 Oct 29.

PMID:
24460692
18.

Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates.

Seghatchian J, Hervig T, Putter JS.

Transfus Apher Sci. 2011 Aug;45(1):75-84. doi: 10.1016/j.transci.2011.06.006. Epub 2011 Jul 22.

PMID:
21782517
19.

Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.

Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, Li J, Goodrich R, Escolar G.

Transfusion. 2005 Jun;45(6):911-9.

PMID:
15934989
20.

Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light.

Cardo LJ, Rentas FJ, Ketchum L, Salata J, Harman R, Melvin W, Weina PJ, Mendez J, Reddy H, Goodrich R.

Vox Sang. 2006 Feb;90(2):85-91.

PMID:
16430665
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk